Grace Therapeutics, Inc.
GRCE Nasdaq
SEC CIK 1444192
Follow Grace Therapeutics
Weekly email: filings, results
Net income
−$2.1M
−127.2% vs same quarter last year
EPS, diluted
−$0.11
−83.3% vs same quarter last year
Operating cash flow
−$1.8M
+43.2% vs same quarter last year
Operating income
−$2.3M
+9.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY26 | −$7.8M |
| FY25 | −$9.6M |
| FY24 | −$12.9M |
| FY23 | −$42.4M |
| FY22 | −$9.8M |
| FY21 | −$19.7M |
| FY20 | −$25.5M |
| FY19 | −$39.4M |
| FY18 | - |